Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
|Articles|May 23, 2022
Daily Medication Pearl: Kazano (Alogliptin and Metformin HCl)
Author(s)Saro Arakelians, PharmD
Kazano is a dipeptidyl-peptidase-4 (DPP-4) inhibitor and a biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Advertisement
Medication Pearl of the Day: Kazano (Alogliptin and Metformin HCl)
Indication: Kazano is a dipeptidyl-peptidase-4 (DPP-4) inhibitor and a biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D).
Insights:
- Dosing: Kazano should be taken twice daily with food.
- Dosage forms: Tablets: 12.5 mg alogliptin and 500 mg metformin HCl, 12.5 mg alogliptin and 1000 mg metformin HCl
- Adverse events: Common adverse reactions reported in ≥4% of patients treated with coadministration of alogliptin with metformin were back pain, diarrhea, headaches, hypertension, nasopharyngitis, upper-respiratory-tract infections, and urinary-tract infections.
- Mechanism of action: Kazano combines 2 antihyperglycemic agents with complementary and distinct 466 mechanisms of action to improve glycemic control in patients with T2D: alogliptin, a selective inhibitor of DPP-4, and metformin HCl, a member of the biguanide 468 class.
- Manufacturer: Takeda Pharma
Advertisement
Related to this article
Phase 3 TRIUMPH-2 data presented at EASD show HbA1c reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
The investigational once-weekly dual GLP-1/GIP receptor agonist, engineered with signaling bias at both receptors, met both primary end points at 48 weeks.
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
September oncology coverage highlighted new breast and kidney cancer combinations, updated lung cancer labeling, and emerging evidence connecting antibiotic exposure with CAR T-cell outcomes.
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
2
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
3
Expert Q&A: Researcher Urges Autonomic Assessment for Patients With Long COVID
4
Sotatercept in ERS PAH Guidelines: What Pharmacists Should Watch
5